Medical/Pharmaceuticals
Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies
CAMBRIDGE, Mass., May 22, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research, announced today that it has entered into a license agreemen...
2024-05-23 07:23
2524
Aiming for New Quality Productivity, Aiding in Reaching the Summit of Global Innovative Pharmaceuticals
Fully Human Antibody Development Platform—NeoMab Bio Officially Opens in Suzhou SUZHOU, China, May 22, 2024 /PRNewswire/ -- On May 22, 2024, NeoMab Biotechnology (Suzhou) Co., Ltd. celebrated its grand opening in Suzhou Industrial Park (BioBAY). This marks a significant milestone that will furthe...
2024-05-22 22:38
2775
Lunit Completes Acquisition of Volpara: Pioneering Next-Level of AI-Driven Cancer Care
SEOUL, South Korea, May 22, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, proudly announces the successful completion of its acquisition of Volpara Health Technologies, a global leader in medical software for breast...
2024-05-22 21:00
3392
Complete Genomics expands to East Coast with new Customer Experience Center in Greater Boston's Biotech Hub
The laboratory gives researchers a training ground for state-of-the-art DNBSEQ technology to further precision diagnostics and treatments SAN JOSE, Calif., May 21, 2024 /PRNewswire/ -- Complete Genomics, a pioneering genomic sequencing company, today announced theMay 22 opening of its Customer E...
2024-05-21 21:00
2965
Ractigen Therapeutics Secures FDA Fast Track Designation for RAG-01, a First-in-Class saRNA Therapy
SUZHOU, China, May 21, 2024 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, proudly announces that its flagship program, RAG-01, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA). This notable a...
2024-05-21 20:00
2562
Cali Biosciences Announces Publication of Successful Phase 2 Study Results in Hernia
SAN DIEGO, May 21, 2024 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali Biosciences"), a biotechnology company dedicated to the research and development of innovative drugs, announced publication of "CPL‑01, an investigational long‑acting ropivacaine, demonstrates saf...
2024-05-21 17:52
1768
NUS scientists discover a novel way of activating muscle cells' natural defences against cancer using magnetic pulses
This drug-free, non-invasive approach could open the doors for new developments in cancer therapy and cancer biomarker discovery SINGAPORE, May 21, 2024 /PRNewswire/ -- A team of researchers led by Associate Professor Alfredo Franco-Obregón from the NUS Institute for Health Innovation & Technolo...
2024-05-21 16:35
2541
Simcere Phar-maceuticals Presented Six Studies on Sanbexin® at ESOC 2024
NANJING, China, May 21, 2024 /PRNewswire/ -- The 10th European Stroke Organization Congress (ESOC), held inBasel, Switzerland from May 15 to 17, 2024 , showcased six studies on Sanbexin® (Edaravone and Dexborneol Concentrated Solution for Injection) and a new dosage form of sublingual tablets unde...
2024-05-21 15:52
2398
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Clearance
YONGIN, South Korea, May 21, 2024 /PRNewswire/ -- GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug (IND) application for their jointly developed MPSIIIA (Sanfilippo Syndrome Type A) treatment, GC1130A. With this FDA clearance,...
2024-05-21 15:12
2327
ZYMFENTRA™ (infliximab-dyyb) demonstrated long-term efficacy and safety profile of maintenance treatment through two years for adults with moderately to severely active Crohn's disease and ulcerative colitis
* Findings from the extended LIBERTY studies and associated post-hoc analysis support the long-term efficacy and safety of ZYMFENTRA™, the first and only FDA-approved subcutaneous infliximab[1],[2] * Data from a post-hoc analysis of the LIBERTY-CD study showed that, despite affecting drug lev...
2024-05-21 12:01
2791
Lunit Achieves Historic Milestone: 100 Peer-Reviewed Papers Published on Its AI Medical Imaging Suite
- From research to real-world impact: Lunit demonstrates Lunit INSIGHT's clinical safety, effectiveness, and efficiency in 100 papers SEOUL, South Korea, May 20, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today ...
2024-05-20 21:00
3396
Duoning Collaborates with Bioelectronica to Commercialize a Single-Cell Sorting System for Antibody Discovery
SHANGHAI, May 20, 2024 /PRNewswire/ -- Duoning Biotechnology Group ("Duoning"), a leading one-stop bioprocess provider inChina, today announced a strategic partnership with Bioelectronica, a company focusing on developing tools for single-cell/single-bacteria research. This partnership aims to en...
2024-05-20 20:00
3147
HaemaLogiX welcomes former Australian Federal Minister for Health Professor the Hon Greg Hunt to the company board as Non-Executive Director
SYDNEY, May 20, 2024 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage biotech developing novel immunotherapies for patients with blood cancers and B-cell diseases, is pleased to announce the appointment of Professor the Hon Greg Hunt, former Australian Federal Minister for Health, to the HaemaLog...
2024-05-20 18:00
3821
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval
YONGIN, South Korea, May 20, 2024 /PRNewswire/ -- GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval. With this approval, development of 'GC1130A' is expected to accelerate with multinational clinical trial...
2024-05-20 14:07
2563
Qilian International plans to adjust industrial investment
JIUQUAN, China, May 17, 2024 /PRNewswire/ -- Qilian International Holdings Group Limited (NASDAQ: QLI) ("Qilian" or the "Company"), a pharmaceutical and chemical products manufacturer headquartered inChina, today announced: In the past two years, Qilian International Holdings Group Limited has en...
2024-05-17 22:00
6902
GV Announces Cooperation with Top 500 Company in China
TORONTO, May 17, 2024 /PRNewswire/ -- Visionary Holdings Inc. (the "Company") (NASDAQ: GV), a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries inCanada and market partners inChina, today announced the Company and Red Sun...
2024-05-17 20:30
4545
OMRON Healthcare's Presence at Heart Rhythm 2024 in the U.S.
KYOTO, Japan, May 17, 2024 /PRNewswire/ -- OMRON Healthcare Co., Ltd. based in Muko,Kyoto Prefecture, Japan, announced its presence at Heart Rhythm 2024, the Annual Meeting of the Heart Rhythm Society (HRS) in the U.S. At Heart Rhythm 2024, the Company will showcase its upper-arm blood pressure m...
2024-05-17 16:00
2647
Celltrion USA announces two-year data for ZYMFENTRA™(infliximab-dyyb) to be presented at Digestive Disease Week (DDW) 2024 Conference
* Data presentations including the extended LIBERTY studies to highlight the long-term treatment goals ofZYMFENTRA™, the first and only FDA-approved subcutaneous infliximab * The data underscores Celltrion's commitment to improving patient outcomes and advancing scientific understanding in th...
2024-05-17 12:01
2571
Full-Life Technologies Announces Appointment of Mark S. de Jong, PhD, as Chief Technical Officer
GEMBLOUX, Belgium, May 16, 2024 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced the appointment ofMark S. de Jong, PhD, to the newly created position of Chief Technical Officer (CTO). Dr. de Jong, joins Full-Life with 43 yea...
2024-05-17 08:00
2413
Visionary Has World-Class Biochip Technology Products
TORONTO, May 16, 2024 /PRNewswire/ -- Visionary Holdings Inc. (the "Company") (NASDAQ: GV), a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries inCanada and market partners inChina, today announced the Company has coopera...
2024-05-16 20:30
3946
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 295 media titles]
2026-09-18 16:29CityUHK and University of Cambridge establish Centre for Advanced and Smart Manufacturing to shape Hong Kong's Industry 5.0 future
[Picked up by 289 media titles]
2026-09-22 18:37
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
CGS International Convenes China-ASEAN Business Leaders Summit to Deepen Capital Connectivity Across the Corridor
[Picked up by 276 media titles]
2026-09-23 09:00
01F Group Announces Investment in DANA, Indonesia's Leading Digital Financial Company, Reinforcing Long-Term Confidence in Asia's Fintech Opportunity
[Picked up by 273 media titles]
2026-09-21 08:00Most Read
COSRX Brings Its 5 Peptide Lip Collection to Ulta Beauty Stores Offline
2026-09-18 22:00
10812
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
2026-09-17 13:09
9960
Ohmyhome Limited Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
2026-09-17 20:00
8152
American Savings Bank Jumps More Than 6% in Trading Debut: NYSE Content Update
2026-09-17 21:21
7730
Sea, Gardens, Lawns and Hearths: Life Abroad Across Noah's N+ Club Network
2026-09-18 23:04
7412